BioSpace News Archive

A platform trial is also efficient in that it enables the investigators to share placebo information.

Proxalutamide, a selective high-affinity silent antagonist of the androgen receptor, is being developed by Chinese biotech, Kintor Pharmaceutical Limited (9939.HK).

Cytokinetics, Incorporated announced that new findings from analyses of claims data and electronic health records related to heart failure and hypertrophic cardiomyopathy were shared in two poster presentations at the American College of Cardiology 70th Annual Scientific Session & Expo.

The Janssen Pharmaceutical Companies of Johnson & Johnson presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO® in combination with aspirin consistently reduced severe vascular events in patients with peripheral artery disease after lower-extremity revascularization compared to aspirin alone regardless of whether it was the first, second, third, or subsequent event.

Global biotherapeutics leader CSL Behring announced the results of a new meta-analysis of seven interventional Phase 3 clinical trials that included more than 82,000 high-risk patients with recent acute coronary syndrome.

Fortress Biotech, Inc., an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, announced financial results and recent corporate highlights for the first quarter ended March 31, 2021.

AffaMed Therapeutics, a global clinical stage biopharmaceutical company dedicated to addressing critical unmet medical needs in ophthalmic, neurological and psychiatric disorders, announced the appointment of Vijay Karwal as Chief Financial Officer.

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

The partnership will enable global genomic sequencing and examination through a specialist platform developed on Oracle Cloud Infrastructure to help mitigate the impact of potentially dangerous COVID-19 variants

Antengene Corporation Limited announced ATG-101, a novel PD-L1/4-1BB bispecific antibody being developed by the company, has completed its quantitative and systems pharmacology modeling that will provide data guiding the first-in-human study of ATG-101.